Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry.
Jaewon OhChan Joo LeeJin Joo ParkSang-Eun LeeMin-Seok KimHyun-Jai ChoJin Oh ChoiHae-Young LeeKyung Kuk HwangKye Hun KimByung-Su YooYoungkeun AhnSang-Hong BaekEun Seok JeonJae-Joong KimMyeong-Chan ChoShung Chull ChaeByung-Hee OhSeok-Min KangPublished in: International journal of heart failure (2019)
Among the Korean hospitalized HFrEF patients, 80% met KFDA label criteria, while only 12% met the inclusion criteria of PARADIGM-HF trial for SV if requiring ≥10 mg enalapril. Sub-optimal pharmacotherapy could be the main reason for ineligible SV use based on the PARADIGM-HF criteria.
Keyphrases
- acute heart failure
- heart failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- tyrosine kinase
- study protocol
- atrial fibrillation
- electronic health record
- machine learning
- deep learning
- smoking cessation
- artificial intelligence
- open label